PURPOSE: To develop and characterize new formulations of ziprasidone with a reduced food effect achieved by increasing exposure in the fasted state. METHODS: Formulations were developed utilizing the following solubilization technologies: inclusion complex of ziprasidone mesylate and cyclodextrin, ziprasidone free base nano-suspension, and semi-ordered ziprasidone HCl in polymer matrix. Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (Geodon®) dosed in the fed state. RESULTS: All formulations containing solubilized ziprasidone showed either no food effect or a reduced food effect compared to commercial capsules. Two formulations when taken in the fasted or fed state were comparable to the commercial capsules dosed in the fed state with respect to total exposure. However, peak concentrations were ~30-40% higher. CONCLUSIONS: Pharmacokinetic studies indicated solubilization technologies can be employed to successfully increase the extent of ziprasidone absorption in the fasted state, thereby reducing the food effect. Such formulations could provide simple and convenient dosing while retaining the familiar safety and efficacy profile of currently marketed capsules.
PURPOSE: To develop and characterize new formulations of ziprasidone with a reduced food effect achieved by increasing exposure in the fasted state. METHODS: Formulations were developed utilizing the following solubilization technologies: inclusion complex of ziprasidone mesylate and cyclodextrin, ziprasidone free base nano-suspension, and semi-ordered ziprasidone HCl in polymer matrix. Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (Geodon®) dosed in the fed state. RESULTS: All formulations containing solubilized ziprasidone showed either no food effect or a reduced food effect compared to commercial capsules. Two formulations when taken in the fasted or fed state were comparable to the commercial capsules dosed in the fed state with respect to total exposure. However, peak concentrations were ~30-40% higher. CONCLUSIONS: Pharmacokinetic studies indicated solubilization technologies can be employed to successfully increase the extent of ziprasidone absorption in the fasted state, thereby reducing the food effect. Such formulations could provide simple and convenient dosing while retaining the familiar safety and efficacy profile of currently marketed capsules.
Authors: Andrea Fagiolini; Fernando Cañas; Bernd Gallhofer; Ilkka Larmo; Pedro Levy; José Manuel Montes; Georgios Papageorgiou; Mathias Zink; Alessandro Rossi Journal: Expert Opin Pharmacother Date: 2010-09 Impact factor: 3.889
Authors: Jeffrey J Miceli; Thomas G Tensfeldt; Thomas Shiovitz; Richard J Anziano; Cedric O'Gorman; Rachel H Harrigan Journal: Clin Ther Date: 2010-03 Impact factor: 3.393
Authors: Saumya Singh; Tapan Parikh; Harpreet K Sandhu; Navnit H Shah; A Waseem Malick; Dharmendra Singhal; Abu T M Serajuddin Journal: Pharm Res Date: 2013-02-21 Impact factor: 4.200